PT  - JOURNAL ARTICLE
AU  - Johns, Jennifer
AU  - Golfetto, Paolo
AU  - Bush, Tia
AU  - Fantozzi, Gianmaurizio
AU  - Shabushnig, John
AU  - Perry, Anthony
AU  - DeGrazio, Fran
AU  - Streich, Dorothee
AU  - Miller, Jahanvi
AU  - Soukiassian, Herve
AU  - Stanton, Amy
AU  - Watson, Rick
TI  - Achieving ″Zero″ Defects for Visible Particles in Injectables
AID  - 10.5731/pdajpst.2018.009027
DP  - 2018 Jan 01
TA  - PDA Journal of Pharmaceutical Science and Technology
PG  - pdajpst.2018.009027
4099  - http://journal.pda.org/content/early/2018/08/29/pdajpst.2018.009027.short
4100  - http://journal.pda.org/content/early/2018/08/29/pdajpst.2018.009027.full
AB  - The reduction of visible particles in injectable products is an important element in the consistent delivery of high-quality parenteral products. An important part of this effort is the control of particles that may emanate from the primary packaging materials. The Parenteral Drug Association (PDA), with the support of the Pharmaceutical Manufacturers Forum (PMF) has undertaken the task of developing test methods to assess the cleanliness of primary packaging components used in the manufacture of sterile injectable products. Further work is focused on end-to-end analysis of the supply chain to identify additional points where particles may enter the finished product workflow. This includes shipment, receipt, transfer and fill and finishing operations. This information and appropriate corrective actions and control methods, coupled with appropriate patient risk-based acceptance limits, are intended to provide better and more consistent supply of injectable products that meet current compendial and Good Manufacturing (GMP) expectations. Aligning control limits between supplier and pharmaceutical manufacturers will offer further improvement. This paper describes the formation of a task force to address these needs and current progress to date.